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Abstract:
Rationale: Patients with type 2 diabetes may co-ingest herbal and 
prescription medicine to control their blood sugar levels. Competitive 
binding of drug and herb may mutually affect their metabolism. This can 
alter the level of drug and its kinetics in the body, potentially causing 
toxicities or loss of efficacy. Understanding how metabolism of 
sulfonylureas like glyburide and gliclazide can be affected by the 
presence of berberine and ice versa can provide valuable information on 
the possible risk of toxicities caused by co-ingestion of drugs. 
Methods: Berberine and sulfonylureas (glyburide and gliclazide) were co-
incubated with rat liver microsomes in the presence of NADPH 
regenerating system. The metabolites of berberine and sulfonylureas 
were analysed using liquid chromatography with high resolution mass 
spectrometry in the positive ion mode. The role of individual isozymes in 
the metabolism of berberine, glyburide and gliclazide was investigated 
by using specific inhibitors. 
Results:  In vitro metabolism of berberine lead to the formation of 
demethyleneberberine (B1a) and B1b through demethylenation. 
Berberrubine (B2a) and its isomer (B2b) was formed through 
demethylation. The isozymes CYP3A and CYP2D were found to be 
involved in the metabolism of berberine. In vitro metabolism of glyburide 
and gliclazide lead to the formation of hydroxylated metabolites. The 
isozymes CYP3A and CYP2C were found to be involved in the metabolism 
of glyburide. Gliclazide was metabolised by CYP2C.  In vitro co-
incubation of glyburide or gliclazide with berberine showed that each 
drugs metabolism was compromised as both share a common isozymes. 
A strong negative linear correlation of glyburide or gliclazide metabolites 
levels and the concentration of berberine confirmed the effect of 
berberine on the metabolism of sulfonylureas. 
Conclusions: The metabolism of sulfonylureas and berberine was 
affected when these compounds were co-incubated with each other. This 
may be attributable to competitive binding of the herb and drug to the 
catalytic sites of same isozymes. 
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Abstract
Rationale: Patients with type 2 diabetes may co-ingest herbal and prescription medicine to 
control their blood sugar levels. Competitive binding of drug and herb may mutually affect 
their metabolism. This can alter the level of drug and its kinetics in the body, potentially causing 
toxicities or loss of efficacy. Understanding how metabolism of sulfonylureas like glyburide 
and gliclazide can be affected by the presence of berberine and vice versa can provide valuable 
information on the possible risk of toxicities caused by co-ingestion of drugs. 
Methods: Berberine and sulfonylureas (glyburide and gliclazide) were co-incubated with rat 
liver microsomes in the presence of NADPH regenerating system. The metabolites of berberine 
and sulfonylureas were analysed using liquid chromatography with high resolution mass 
spectrometry in the positive ion mode. The role of individual isozymes in the metabolism of 
berberine, glyburide and gliclazide was investigated by using specific inhibitors. 
Results:  In vitro metabolism of berberine lead to the formation of demethyleneberberine (B1a) 
and B1b through demethylenation. Berberrubine (B2a) and its isomer (B2b) was formed 
through demethylation. The isozymes CYP3A and CYP2D were found to be involved in the 
metabolism of berberine. In vitro metabolism of glyburide and gliclazide lead to the formation 
of hydroxylated metabolites. The isozymes CYP3A and CYP2C were found to be involved in 
the metabolism of glyburide. Gliclazide was metabolised by CYP2C.  In vitro co-incubation of 
glyburide or gliclazide with berberine showed that each drugs metabolism was compromised 
as both share a common isozymes. A strong negative linear correlation of glyburide or 
gliclazide metabolites levels and the concentration of berberine confirmed the effect of 
berberine on the metabolism of sulfonylureas. 
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Conclusions: The metabolism of sulfonylureas and berberine was affected when these 
compounds were co-incubated with each other. This may be attributable to competitive binding 
of the herb and drug to the catalytic sites of same isozymes.
1. Introduction 
Many patients use herbal medicines alongside prescription medicines to treat their medical 
conditions. The co-administration of these compounds can cause competitive metabolism as 
cytochrome P450 (CYP) is the main family of isozymes responsible for the biotransformation 
of compounds 1. One therapeutic area where both herb and prescription medicine may be co-
ingested is in the treatment of type 2 diabetes. Sulfonylureas (glibenclamide (glyburide) and 
gliclazide) are used as the frontline pharmacotherapy to treat adult type 2 diabetes2-4.  
Sulfonylureas stimulate pancreatic β-cells to increase insulin secretion, which causes the 
depolarisation of β-cell membrane through inhibition of KATP channels.  This leads to the 
opening of Ca2+ channel voltage gate which in turn results in the influx of Ca2+ inside the cells. 
Exocytosis is achieved as insulin-containing secretory granules are released in circulation 5.  
The efficacy of sulfonylureas is determined from β cell function 6. Sulfonylureas are mainly 
eliminated through metabolic transformation.  Studies that have been reported on metabolism 
of glyburide have confirmed the production of 10 hydroxylated metabolites catalysed by 
CYP3A4/5/7, CYP2C9, CYP2C8 and CYP2C19 (Fig. 1A) 7-11 Gliclazide has been shown to be 
extensively metabolised by the activity of CYP2C9 and CYP2C19 to produce a range of 
hydroxylated metabolites (Fig. 1B) 3,12-14.  Berberine is an active alkaloid component (Fig. 1C) 
found in certain plants such as Phellodendron cortex (Huang Bai), Coptis chinensis (Huang 
Lian), Hydrastis canadensis, Berberis aquifolium, Berberis vulgaris and Berberis aristata 15,16.  
Berberine has shown to have anti-diabetic effects 16,17.
The hypoglycaemic effect of berberine is attributed to: activation of AMPK (AMP-activated 
protein kinase)18, β cell regeneration 19and increase of muscle glucose uptake 20. Berberine 
inhibits dipeptidyl peptidase 4 (DPP-4) to regulate the secretions of glucagon-like peptide 
(GLP-1) 21, 22. In addition, berberine inhibits the aerobic respiration, and induces the glycolysis 
through glucose uptake 18,23-25. Berberine is metabolised by CYP2D6, CYP1A2, CYP2E1, 
CYP2C9, CYP2C19 and CYP3A4 to produce demethylated and demethylenated metabolites 
26. Competitive metabolism may mutually affect the metabolism of both compounds. This can 
change the level of the drug and its kinetics in the body to cause toxicity or loss of efficacy 1. 
To date, there is no study that has been reported on how the competitive metabolism of 
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berberine and the sulfonylureas (glyburide and gliclazide) would affect the metabolism of both 
compounds as they share the same isozymes. The aim of this paper was to investigate the in 
vitro interaction of berberine-sulfonylureas by considering that binding of one drug to the 
catalytic site of isozyme could compromise the metabolism of the other drug.
2 Materials and Methods 
 2.1 Materials 
 Male and female rat (Sprague-Dawley) liver microsomes, glucose-6-phosphate dehydrogenase 
(G-6-PD)  from leuconostoc mesenteroides - recombinant, expressed in E. coli, ammonium 
sulphate suspension, D-glucose 6-phosphate sodium salt, β-nicotinamide adenine dinucleotide 
2′-phosphate reduced tetras dium salt hydrate (β-NADPH), magnesium chloride, berberine 
chloride hydrate, glyburide, glipizide, gliclazide, ketoconazole, tienilic acid,  quinidine and 
cimetidine were obtained from Sigma-Aldrich (Seldown Lane, Poole, UK). Acetonitrile of 
HPLC grade, formic acid and methanol were purchased from Fisher Scientific (Loughborough, 
Leicestershire, UK). Mini-Uni 0.45 µm prep syringeless filter were supplied by GE Healthcare 
Life Sciences (Little Chalfont, Bukinghamshire, UK). ACE3 C18-AR Column and ACE3 C18 
guard column were purchased from Hichrom Limited (Lutterworth, Leicestershire, UK). 
Sodium hydroxide and potassium phosphate monobasic of analytical reagent grade were 
obtained from BDH and Griffin (Ealing,Middlesex, UK) respectively. Berberrubine chloride 
and demethyleneberberine were custom manufactured by AvaChem Scientific (San Antonio, 
Texas, USA).  GraphPad Prism 7.04® and Minitab 17® were purchased from GraphPad 
Software (San Diego, CA, USA) and Minitab Ltd. (Progress Way, Coventry, UK) respectively. 
2.2 Preparation of drugs
Stock solutions of berberine, cimetidine, gliclazide, glyburide, ketoconazole, quinidine, and 
tienilic acid were prepared at a concentration up to 2 mg/mL in methanol. Working solutions 
at a concentration of 0.6 mg/mL were prepared by diluting the stock solution with water. A 
single solution of cimetidine was prepared at a concentration of 1 mg/mL in deionised water. 
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2.3 LC–IT-TOF MS instrumentation and conditions 
Samples were analysed using a Shimadzu LC-IT-TOF MS. (Milton Keynes, Bukinghamshire, 
UK). A Shimadzu Prominence HPLC system composed of a degassing unit (model number 
L202543), pumps (model number L201044), autosampler (model number L201743),  column 
oven (model number L202043), detector (model numberL201343) and system controller 
(model number L202344) hyphenated to an ion-trap time of flight mass spectrometer (model 
number C20234470341) (IT-TOF MS) was used.  LC-MS solutions software V3® was used 
to acquire data and set the instrument parameters. Separation of sample was carried out using 
an ACE3 C18 150 x 2.1 mm, 3 µm column with a ACE3 C18 cartridge guard column. The 
mobile phase consisting of 0.1% formic acid in water (eluent A) and 0.1% formic acid in 
acetonitrile (eluent B) was used at a flow rate of 0.21 mL/min. A linear gradient elution profile: 
0-10 min, 25 to 90 % B; 10-15 min, 90 % B; 15 to 15.10 min, 25 % B. The column and 
autosampler temperature were maintained at 40 and 4°C respectively. The sample injection 
volume was 10 µL.  The mass spectrometer was equipped with an electrospray ionisation 
source (ESI) and was operated in dual positive and negative ion acquisition mode. MS and 
MS/MS data was acquired in the range m/z 100 to 590 with an ion accumulation time of 30 
msec.  Analysis was carried out using nitrogen as nebuliser gas at a flow rate of 1.5 L/min and 
curved desorption line (CDL) and heat block temperature of 200°C. The detector and interface 
voltage was set at 1.60 and 4.5 kV respectively. Argon was used as collision gas at 75 psi.  A 
mixture of acetonitrile, isopropanol and water (33.3:33.3:33.3, v/v) containing 0.1% formic 
acid was used for the injection needle rinse. 
2.4 In vitro metabolism conditions of selected drugs
2.4.1 Incubation conditions
A co-factors solution composed of 5 mM magnesium chloride, 2 mM NADP, disodium salt 
and 5 mM D-glucose 6-phosphate sodium salt was prepared in 0.1 M potassium phosphate 
buffer, pH 7.4. NADPH regenerating system was prepared by adding glucose-6-phosphate 
dehydrogenase (1 U/mL) to the co-factors solution. A small volume (50 µL) of cofactors 
solution together with 50 µL of G-6-PD and 40 µL of 0.1 M KH2PO4 buffer, pH 7.4 was 
transferred to a 1.5 mL Eppendorf tube. An aliquot (50 µL) of microsomes (0.5 mg/mL) was 
then added. The incubation mixture was pre-incubated for 5 min in a water bath at 37°C and 
subsequently berberine or sulfonylurea (glyburide or gliclazide) was added at  a final 
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concentration of 20 µM.  The final volume of incubation mixture was 0.2 mL.  A small volume 
(20 µL) of reaction termination solvent consisting of a mixture of water, acetonitrile and formic 
acid (92:5:3 %, v/v) was added after 1 h. The samples were subsequently kept on ice for 10 
min. Ice cold methanol (60 %, v/v) was then added and the mixture was placed on ice for 10 
min. Samples were centrifuged at 16,000 g for 5 min and supernatant was collected and filtered 
using Mini-Uni prep syringeless filters (0.45µm) to remove precipitated proteins before loading 
10 µL of sample onto the HPLC column.
2.5 Role of CYP isozymes in the metabolism of sulfonylureas and berberine
In vitro phase I metabolism profile of berberine, glyburide and gliclazide was established by 
incubating 20 µM of these compounds with 0.5 mg/mL male rat liver microsomes and the 
NADPH regenerating system. To investigate which isozymes are involved in the metabolisms 
of berberine, glyburide and gliclazide, specific isozyme inhibitors were used. Ketoconazole, 
quinidine, cimetidine and tienilic acid are specific inhibitors for isozymes CYP3A, CYP2D, 
CYP1A2 and CYP2C respectively. To the in vitro incubation mixture containing 20 µM 
berberine or glyburide or gliclazide and NADPH regenerating system, ketoconazole, quinidine, 
cimetidine or tienilic acid were added at various concentrations to estimate the involvement of 
isozymes of CYP3A, CYP2D, CYP1A2 and CYP2C respectively. The mixture was incubated 
as described above. The concentration of the inhibitors used was validated in preliminary 
experiments to obtain the IC50 values.  
2.6 Berberine-sulfonylureas interactions 
The interactions of glyburide and gliclazide with berberine were studied by incubating the 
sulfonylureas (20 µM) with various concentrations of berberine (0.1 to 80 µM) in the presence 
of 0.5 mg/mL microsomes and the NADPH regenerating system. Control samples were 
prepared with berberine and sulfonylurea alone in the same concentration range with 0.5 
mg/mL microsomes and the NADPH regenerating system. All samples were prepared in 
triplicate.  
2.7 Measurement of berberine and sulfonylureas metabolites 
Demethyleneberberine and berberrubine were prepared over a concentration range 0.31 to 20 
µg/mL and 0.11 to 28 µg/mL respectively. The internal standard, glipizide, was spiked into all 
the standards at a final concentration of 5.6 µg/mL. These were used to generate standard 
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curves. The level of glyburide metabolites (4-trans-hydroxycycohexyl glyburide, 4-cis-
hydroxycyclohexyl glyburide and 3-trans-hydroxycycohexyl glyburide) and gliclazide 
metabolites 6-α- hydroxygliclazide and methylhydroxygliclazide were semi-quantitated due to 
unavailability of the authentic standards. The change in HPLC-peak area of metabolite relative 
to the control was calculated. Although the metabolites such as 3-cis-hydroxycyclohexyl 
glyburide, 6-β- hydroxygliclazide, 7- β-hydroxygliclazide, 7-α-hydroxygliclazide were 
detected and not quantitated due to insufficient separation (Fig. 2,3). 
2.8 Data treatment  
The statistical significance of the data was established by using GraphPad Prism 7.04® and 
Minitab 17®. The normal distribution of data was verified by probability plots. All data are 
represented as mean ± SD. Two samples t-test and Pearson correlation tests were used to 
determine the statistical significance at 95% confidence interval with p values (0.05).  The p 
values were used with following symbols; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P≤ 
0.0001 and P > 0.05 was not significant. 
3 Results and Discussion
3.1 In vitro phase I metabolism profile of berberine and sulfonylureas
Glyburide and gliclazide metabolites eluted in the increasing order of hydrophobicity using 
reverse phase chromatography with a linear gradient elution profile from 25 to 90 % of 
acetonitrile (containing 0.1 % formic acid) over 15 min. Sulfonylureas metabolites were 
identified from both the MS and MS/MS spectra.
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3.2 In vitro phase I metabolism profile of glyburide 
Glyburide and its metabolites eluted in the following order G1a<G1b<G1c<G1d<G (Fig. 2 and 
Table 1). Metabolites of glyburide were identified from both the MS and MS/MS spectra. The 
elution order of the hydroxylated metabolites of glyburide has been reported using reverse 
phase chromatography 9,27. These authors determined the isomeric nature of the metabolites 
using synthesised standards. In the present study, using similar separation conditions the 
elution profile for glyburide and its metabolites is likely to be similar.  Glyburide eluted at 10.0 
min and showed [M+H]+ ion at m/z 494.151 (C23H29CIN3O5S). Fragmentation of this precursor 
ion yielded the product ions at m/z 395.048, 369.065, 169.005 as shown in Fig. 2. The mass 
spectrum obtained can be explained by fragmentation of glyburide precursor ion. The ion m/z 
395.048 is formed via the loss of C6H13N (99 Da), m/z 369.065 results from the loss of 
C7H11NO (125 Da), m/z 169.005 via the loss of C15H23N3O3S (325 Da).  Identical fragments 
have been reported by other authors28, 29.  
MS and MS/MS Spectra and fragmentation pathway of glyburide metabolites following 
incubation of glyburide with rat male liver microsomes and the NADPH regenerating system 
are shown in Fig. S-1. 4-trans-hydroxycyclohexyl glyburide (G1a) (m/z 510.143) and its 
isomers G1b (4-cis-hydroxycyclohexyl glyburide), G1c (3-cis-hydroxycyclohexyl glyburide) 
and G1d (3-trans-hydroxycyclohexyl glyburide) eluted at 7.5, 7.8, 7.9 and 9.1 min and showed 
[M+H]+ ion  respectively.  The increase in mass of glyburide by 16 Da to form the isomeric 
metabolites can be attributed to hydroxylation of the compound 8-10.  The MS and MS/MS 
spectra and retention time was used to identify the hydroxylated metabolites of glyburide. From 
identical MS and MS/MS spectra of G1a, G1b, G1c and G1d it was evident that these were 
isomers. Fragmentation of this precursor ion yielded the product ions at m/z 492.133, 410.040, 
385.060, 369.064 as shown in Fig. S-1. The mass spectrum obtained can be explained by 
fragmentation of glyburide metabolites precursor ion i.e. m/z 492.133 formed via the loss of 
H2O (18 Da), m/z 411.040 formed via the loss of C6H13N (99 Da), m/z 385.060 via the loss of 
C7H11NO (125 Da), m/z 369.064 via the loss of C7H11NO2 (141 Da). Precursor ion was 
hydroxylated at the terminal region of cyclohexyl group 29,30. The product ions m/z 411.040 
and 385.060 have been reported by 28. Structure of product ions m/z 385.060 and m/z 369.064 
proposed are identical to those reported by 27.
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3.3 In vitro phase I metabolism profile of gliclazide
Gliclazide and its metabolites eluted in the following order Gz1a<Gz1b<Gz1c<Gz1d 
<Gz1e<Gz (Fig. 3 and Table 1). The elution order of the hydroxylated metabolites of gliclazide 
has been reported using reverse phase chromatography31-33.  The authors determined the elution 
order of the metabolites using synthesised standards. In the present study, using similar reverse 
phase conditions a similar elution profile for gliclazide and its metabolites was obtained. 
Gliclazide eluted at 9.3 min as [M+H]+ ion at m/z 324.135 (C15H22N3O3S). Fragmentation of 
this precursor ion yielded the product ions at m/z 281.128, 168.112, 151.086, 127.122, 110.022 
as shown in Fig.3. The mass spectrum obtained can be explained by the mass changes of  
gliclazide precursor ion i.e. m/z 281.128 via the loss of C3H7 (43 Da) , m/z 168.112 via the loss 
of C7H8O2S (156 Da), m/z 151.086 via the loss of C7H11NO2S (173 Da), m/z 127.122 via the 
loss of C8H7NO3S (197 Da), m/z 110.020 via the loss of C8H10N2O3S (214 Da). Identical 
fragments were reported by 34-36.
6-α-hydroxygliclazide (Gz1a) (m/z 340.129)  as a metabolite of gliclazide with its isomers 6- 
β-hydroxygliclazide (Gz1b), 7-α-hydroxygliclazide (Gz1c), 7-β-hydroxygliclazide (Gz1d) and 
methylhydroxygliclazide (Gz1e) eluted at 5.5 , 5.9, 6.0 , 6.4  and 6.8 min and showed  [M+H]+  
ion at m/z 340.131 respectively. These metabolites are mostly likely produced through 
hydroxylation of gliclazide (m/z 324.135) 14,33. The MS/MS spectrum and retention time was 
used to identify the hydroxylated metabolites of gliclazide and from identical MS and MS/MS 
spectra it was evident that Gz1a, Gz1b, Gz1c, Gz1d, Gz1e were isomers. Fragmentation of this 
precursor ion yielded the product ions at m/z 322.119, 110.095, 143.119, 168.113 as shown in 
Fig. S-2. The mass spectrum obtained can be explained by fragmentation of gliclazide 
metabolites i.e. m/z 322.119 formed via the loss of H2O (18 Da), m/z 110.095 via the loss of 
C8H10N2O4S (230 Da), m/z 143.119 via the loss of  C8H7NO3S (197 Da), m/z 168.113 via the 
loss of C7H8O3S (172 Da). 
3.4 In vitro phase I metabolism profile of berberine 
Berberine metabolites eluted in the following order B1a<B1b<B2a<B2b<B.  MS and MS/MS 
spectra was used to identify the analytes (Fig. 4 and Table 1). Berberine eluted at 6.8 min and 
showed [M+] at m/z 336.123 (C20H18NO4).  Fragmentation of this precursor ion yielded the 
product ions at m/z 321.100, 305.102, 292.097, 275.084 as shown in Fig 4. The mass spectrum 
obtained can be explained by the mass changes from the berberine precursor ion i.e. m/z 
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321.100 via the loss of CH3 (15 Da), m/z 305.102 via the loss of CH3O (31 Da), m/z 292.097 
via the loss of C2H4O (44 Da) and m/z 275.084 via the loss of C2H5O2 (61 Da). Identical 
fragments were reported by 16.
 Demethyleneberberine (C19H18NO4) (B1a) m/z 324.122 and B1b were produced following in 
vitro incubation of berberine with rat male liver microsomes and the NADPH regenerating 
system. B1a and B1b eluted at 4.9 and 5.8 min respectively and showed [M]+ ion at m/z 
324.122. The MS and MS/MS spectra of B1a and B1b were identical. B1a was produced 
through demethylenation and this was confirmed using authentic standard. B1b showed similar 
empirical formula based on accurate mass from B1a and eluted after 0.9 min. This could be 
due to a different or additional biotransformation. To date B1b has not been reported in the 
literature. The catechol of B1a could be methylated by catechol-O-methyl transferase and 
demethylated at the other end of the molecule to give B1b (Fig. 7). The most abundant product 
ions of demethyleneberberine was observed at m/z 309.109 via the loss of CH3 (15 Da) and m/z 
281.101 via the loss of C2H3O (43 Da) (Fig. S-3). 
 Berberrubine (C19H16NO4) (B2a) m/z 322.107 and its isomer thalifendine (B2b) was produced 
following in vitro incubation of berberine with rat male liver microsomes and the NADPH 
regenerating system through demethylation (Fig. S-4).  Berberrubine showed [M]+ ion at m/z 
322.107. This was apparent from 14 Da lower mass (m/z 322.107) than the parent compound 
(m/z 336.124) and from MS and MS/MS spectra of authentic standards16,37.  B2a and B2b eluted 
at 5.9 and 6.2 min respectively. MS and MS/MS spectra and retention time of berberrubine was 
similar to the authentic standard. The identical MS and MS/MS spectra of berberrubine 
confirmed that B2a and B2b were isomers and showed similar fragmentation pattern. The most 
abundant product ion of berberrubine was observed at m/z 307.087 via the loss of CH3 (15 Da) 
(Fig. S-4).  
3.5 Role of CYP isozymes involved in the metabolism of sulfonylureas
The role of CYPs in producing hydroxylated metabolites of glyburide and gliclazide was 
investigated using ketoconazole and tienilic acid as CYP3A and CYP2C inhibitors respectively 
37-39. The IC50 values of ketoconazole and tienilic acid to inhibit the production of glyburide 
metabolites are shown in S-Table 1. The hydroxylation metabolism of glyburide mediated by 
CYP3A and CYP2C is depicted in S-Fig. 6. From these results it has been seen that CYP3A 
and CYP2C play a key role in the metabolism of glyburide. These findings are consistent with 
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previous studies that have been conducted using human liver microsomes and in pregnant 
women by 9,11. The IC50 values of tienilic acid to inhibit the production of gliclazide 
metabolites are listed in S-Table 1. The metabolism of gliclazide mediated by CYP2C to 
produce the hydroxylated metabolites is shown in S-Fig.7. The results obtained demonstrate 
that CYP2C is involved in the metabolism of gliclazide.
3.6 Role of CYP isozymes in metabolism of berberine 
Cimetidine has been shown to be a reversible competitive inhibitor of CYP1A2 41. The role of 
CYP1A2 in the metabolism of berberine was verified by correlation analysis of the production 
of berberine metabolites and the concentrations of cimetidine present in the in vitro incubation 
mixture. A weak positive correlation was noticed with no statistical significance (p- value > 
0.05) (see Fig. S-5). The increasing concentration of cimetidine did not show any significant 
decrease in the formation of berberine metabolites.  The role of CYP1A2 in the metabolism of 
berberine was only mentioned by 37, no similar findings were observed in the present study.
As a highly selective competitive inhibitor of CYP2D6 39,40, quinidine was found to inhibit the 
metabolism of berberine (S-Table 1). The isozyme CYP3A was also found to play a role in the 
metabolism of berberine. The presence of ketoconazole an inhibitor of CYP3A, in the 
incubation mixture resulted in inhibition of the production of B1a, B1b, B2a, B2b (S-Table 1). 
A study conducted by 37 using mice and human liver microsomes identified that CYP3A4 is 
involved in the metabolism of berberine. This is consistent with our findings. The metabolism 
of berberine mediated by CYP2D and CYP3A is shown in S-Fig.8.
3.7 Interactions of berberine and sulfonylureas  
3.7.1 Measurement of berberine metabolites 
Separate standard curves were derived for demethyleneberberine and berberrubine in the 
berberine vs glyburide and –gliclazide interactions study. The correlation coefficient values 
were >0.99. 
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3.7.2 Interactions of berberine and glyburide 
Berberine and glyburide share the common isozyme CYP3A4 in their metabolism 11,37. The 
potential interaction in the metabolism of berberine and glyburide was investigated by co-
incubating berberine with glyburide with rat liver microsomes. It was found that the 
metabolism of berberine was affected by the presence of glyburide. Lower levels of 
demethyleneberberine and berberrubine were observed when berberine was co-incubated with 
20 µM glyburide confirming statistical significance, p < 0.05 for 2 and 4 µM respectively of 
berberine. There was no statistical significance for the difference in metabolism of berberine 
at 6, 8 and 10 µM in the presence of glyburide at 20 µM (Fig. 5).
The effect of berberine on the production of glyburide metabolites was verified using the 
correlation analysis of glyburide metabolites production and the concentration of berberine 
present in the in vitro metabolism incubation mixture (S-Table 2). A strong negative linear 
relationship with a correlation coefficient of (r = -0.96) was observed between the production 
of glyburide metabolites, including both 4-trans-hydroxycyclohexyl glyburide and 4-cis-
hydroxycyclohexyl glyburide, and the concentrations of berberine (2-10 µM). However, there 
was no significant statistical difference in the formation of 3-trans-hydroxycyclohexyl 
glyburide in presence and absence of berberine. 
The results from interaction study, suggest that the competitive binding of glyburide and 
berberine to isozyme CYP3A may be responsible for the lower biotransformation of both 
compounds when they are co-incubated with microsomes.
3.7.3 Interactions of berberine and gliclazide
The isozyme CYP2C9 has been shown to mediate the metabolism both of berberine and 
gliclazide 17, 26, 37. In the current work potential interactions between berberine and gliclazide 
were investigated by co-incubating the two compounds with rat liver microsomes. The 
interactions were investigated with berberine in the range 2-80 µM in the presence of gliclazide 
at 20 µM. It was found that the metabolism of berberine at 10 µM was affected by the presence 
of 20 µM gliclazide. A lower level of demethyleneberberine was formed when berberine was 
co-incubated with gliclazide. This was found to be statistically significant with a p < 0.05.  B1b 
was also formed at lower level in presence of 20 µM gliclazide and berberine at concentration 
of 2, 40 and 80 µM with statistical significance of p < 0.05. Berberrubine isomer was formed 
at lower level following the incubation of berberine at concentration of 2, 6, 10, 20 and 40 µM  
in presence of 20 µM gliclazide confirming statistical significance, p < 0.05 (Fig. 6). 
Page 12 of 24
http://mc.manuscriptcentral.com/rcm































































The effect of berberine on the production of gliclazide metabolites was verified using the 
correlation analysis (S-Table 2). The strong negative linear relationship between formation of 
gliclazide metabolites and the concentration of berberine (2-80 µM) was observed with a 
correlation coefficient of r = -0.80. There was a significant decrease in the formation of (6-α- 
hydroxygliclazide) (Gz1c) and methylhydroxygliclazide (Gz1e), indicating that berberine 
inhibited the metabolism of gliclazide. This may be attributable to berberine and gliclazide 
competing for binding to the same CYP2C isozyme. 
The studies conducted by 17,26,37  on the role of isozymes involved in the metabolism of 
berberine have confirmed the role of CYP2C. Although berberine affected the metabolism of 
gliclazide, this sulfonylurea did not significantly affect the metabolism of berberine . This may 
be because  several isozymes (CYP3A4, CYP2D6, CYP2C19, CYP2E1) are involved in the 
metabolism of berberine 37. This may help to explain why gliclazide did not significantly affect 
the metabolism of berberine.
3.8 Conclusions
In vitro metabolic profiles of berberine and sulfonylureas (glyburide, gliclazide) were 
established  using liquid chromatography with high resolution mass spectrometry in the 
positive ion mode.  This was utilised to study the potential interactions of berberine and 
sulfonylureas. Glyburide and berberine both share a common CYP3A isozyme and due to this 
their metabolism was mutually affected when both compounds were co-incubated with  rat 
microsomes. Co-incubation of berberine and gliclazide with microsomes resulted in inhibition 
of metabolism of gliclazide. This may be attributable to the two compounds competing for the 
same isozyme CYP2C, which is the only isozyme that is involved in the metabolism of 
gliclazide The molecular mechanisms of berberine and sulfonylurea interactions could be 
attributable to the compounds sharing the same isozymes.  The herbs containing berberine and 
other active components may give different results as a complex mixture. Further in vitro and 
vivo interaction studies are necessary to gain better understanding of the impact of drug-herb 
interactions on their metabolism. 
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Table 1 LC MS/MS retention times and precursor and product ions of berberine and 
sulfonylureas.







Berberine (B) 6.8 336.123 336.124 2.03 C20H18NO4
Demethyleneberberine (B1a) 4.9 324.123 324.122 1.49 C19H18NO4
B1b 5.9 324.123 324.122 1.49 C19H18NO4
Berberrubine (B2a) 5.9 322.107 322.107 0.41 C19H16NO4
Berberrubine’s isomer (B2b) 6.2 322.107 322.107 0.41 C19H16NO4
Glyburide (G) 10.0 494.151 494.151 0.09 C23H29CIN3O5S
4-trans-hydroxycyclohexyl glyburide (G1a) 7.5 510.146 510.146 0.90 C23H29CIN3O5S
4-cis-hydroxycyclohexyl glyburide (G1b) 7.8 510.146 510.146 0.90 C23H29CIN3O5S
3-cis-hydroxycyclohexyl glyburide (G1c) 7.9 510.146 510.146 0.90 C23H29CIN3O5S
3-trans-hydroxycyclohexyl glyburide (G1d) 9.1 510.146 510.146 0.90 C23H29CIN3O5S
Gliclazide (G) 9.2 324.138 324.137 0.88 C15H22N3O3S
6-β- hydroxygliclazide(Gz1a) 5.5 340.133 340.132 2.35 C15H22N3O4S
7- β- hydroxygliclazide (Gz1b) 5.9 340.133 340.132 2.35 C15H22N3O4S
6-α- hydroxygliclazide (Gz1c) 6.1 340.133 340.132 2.35 C15H22N3O4S
7-α- hydroxygliclazide (Gz1d) 6.4 340.133 340.132 2.35 C15H22N3O4S
Methylhydroxygliclazide(Gz1e) 6.8 340.133 340.132 2.35 C15H22N3O4S
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Fig.1 Chemical structures of berberine and sulfonylureas. 
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Fig. 2 Metabolic profile of glyburide. Extracted ion chromatogram (EIC) of glyburide (20 µM) and its 
metabolites following incubation with rat male liver microsomes (G= glyburide, G1a,G1b, G1c, G1d= 
metabolites) (A); MS and MS/MS spectra of glyburide (m/z 494.151) acquired  using positive ion mode (B); 
structure of product ions (C). 
571x807mm (96 x 96 DPI) 
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Fig. 3 Metabolic profile of gliclazide. Extracted ion Chromatogram of (EIC) gliclazide (20 µM) and its 
metabolites following incubation with rat male liver microsomes (Gz= gliclazide, Gz1a, Gz1b, Gz1c, Gz1d, 
Gz1e = metabolites) (A); MS and MS/MS spectra of gliclazide (m/z 324.135) acquired using positive ion 
mode (B); structure of product ions (C). 
924x1753mm (96 x 96 DPI) 
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Fig. 4 Metabolic profile of berberine. Extracted ion chromatogram (EIC) of berberine (20 µM) and its 
metabolites following incubation with rat male liver microsomes (B= berberine, B1a, B1b, B2a, B2b = 
metabolites). (A); MS and MS/MS spectra of berberine (m/z 336.124) acquired using positive ion mode (B); 
structure of product ions (C). 
987x1963mm (96 x 96 DPI) 
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Fig. 5 Plots of berberine metabolites as a function of concentration of berberine following co-incubation of 
berberine (Ber) (2- 10 µM) with glyburide (Glb) 20 µM. The control represents the normal metabolism of 
berberine in the absence of glyburide at a fixed concentration. Each data point in the plots represents the 
mean value of three replicates; (A) Demethyleneberberine (B1a); (B) Berberrubine (B2a); (C) B1b and (D) 
B2b represent relative percentag  change. 
373x300mm (96 x 96 DPI) 
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Fig. 6 Plots of berberine metabolites as a function of concentration of berberine following co-incubation of 
berberine (Ber) (2 to 80 µM) with gliclazide (Gli) at a fixed concentration of 20 µM. The control represents 
the normal metabolism of berberine in the absence of gliclazide at the same concentration range.  Each data 
point in the bar chart represents the mean value of three replicates; (A) Demethyleneberberine (B1a); (B) 
Berberrubine (B2a); (C) B1b and (D) B2b represent relative percentage change. 
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Fig. 7 Proposed structure of B1b. 
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